MedPage Today on MSN
A Hit and a Miss for Liquid Biopsy to Guide Adjuvant Cancer Therapy
Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...
Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback